Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate

被引：1
|
作者：
Brand, Toni M. [1 ]
Wheeler, Deric L. [1 ]
机构：
[1] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Ctr Comprehens Canc, Madison, WI 53201 USA
来源：
CANCER BIOLOGY & THERAPY | 2011年 / 11卷 / 03期
关键词：
breast cancer; epidermal growth factor receptor (EGFR); lithium citrate; PIK3CA; receptor tyrosine kinase (RTK); METASTATIC COLORECTAL-CANCER; LUNG-CANCER; CETUXIMAB; MUTATIONS; KRAS; THERAPY;
D O I：
10.4161/cbt.11.3.14696
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：368 / 370
页数：3
相关论文
共 50 条
  • [41] Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer
    Tan, Elaine S.
    Fan, Wenyi
    Knepper, Todd C.
    Schell, Michael J.
    Sahin, Ibrahim H.
    Fleming, Jason B.
    Xie, Hao
    TARGETED ONCOLOGY, 2022, 17 (04) : 483 - 492
  • [42] Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer
    Lu, Weipeng
    Wei, Hong
    Li, Mei
    Wang, Hai
    Liu, Lina
    Zhang, Qiuping
    Liu, Lisha
    Lu, Shen
    MOLECULAR MEDICINE REPORTS, 2015, 12 (01) : 1219 - 1224
  • [43] Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond
    Katsios, Christos
    Ziogas, Dimosthenis E.
    Roukos, Dimitrios H.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (05) : 525 - 529
  • [44] Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma - occurence and prognostic significance
    Modos, Orsolya
    Reis, Henning
    Niedworok, Christian
    Ruebben, Herbert
    Szendroi, Attila
    Szasz, Marcell A.
    Timar, Jozsef
    Baghy, Kornelia
    Kovalszky, Ilona
    Golabek, Tomasz
    Chlosta, Piotr
    Okon, Krzysztof
    Peyronnet, Benoit
    Mathieu, Romain
    Shariat, Shahrokh F.
    Hollosi, Peter
    Nyirady, Peter
    Szarvas, Tibor
    ONCOTARGET, 2016, 7 (26) : 39293 - 39301
  • [45] Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
    VanderLaan, Paul A.
    Rangachari, Deepa
    Mockus, Susan M.
    Spotlow, Vanessa
    Reddi, Honey V.
    Malcolm, Joan
    Huberman, Mark S.
    Joseph, Loren J.
    Kobayashi, Susumu S.
    Costa, Daniel B.
    LUNG CANCER, 2017, 106 : 17 - 21
  • [46] PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis
    Mohammed A. Aleskandarany
    Emad A. Rakha
    Mohamed A. H. Ahmed
    Desmond G. Powe
    Emma C. Paish
    R. Douglas Macmillan
    Ian O. Ellis
    Andrew R. Green
    Breast Cancer Research and Treatment, 2010, 122 : 45 - 53
  • [47] A Novel PIK3CA Hotspot Mutation in Isfahanian Breast Cancer Patients
    Gharbi, Sedigheh
    Faghihi, Mehri
    Tavassoli, Manoochehr
    CANCER INVESTIGATION, 2011, 29 (04) : 313 - 317
  • [48] TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing
    Savli, Hakan
    Sertdemir, Nilufer
    Aydin, Duygu
    Dursun, Bilge
    Kurtas, Omer
    Reka, Seda
    Sunnetci-Akkoyunlu, Deniz
    Eren-Keskin, Seda
    Uygun, Kazim
    Ozden, Ercan
    Isik, Ulas
    Cabuk, Devrim
    Demir, Gulhan
    Guzdolu, Eda
    Gokbayrak, Merve
    Aksu, Maksut Gorkem
    Canturk, Nuh Zafer
    Cine, Naci
    JOURNAL OF BIOTECHNOLOGY, 2019, 300 : 87 - 93
  • [49] Epigenetic Therapy in Hormone Positive Breast Cancer: The Role of PIK3CA
    Blawski, Ryan
    Toska, Eneda
    CURRENT BREAST CANCER REPORTS, 2025, 17 (01)
  • [50] The role of PIK3CA mutations in the development of breast cancer (a literature review)
    Pryvalova, A. O.
    Vynnychenko, I. O.
    Harbuzova, V. Yu
    Vynnychenko, O., I
    Moskalenko, Yu, V
    ZAPOROZHYE MEDICAL JOURNAL, 2020, 22 (04) : 554 - 560
12345